CAMK2G and schizophrenia: Indeed, the heterozygous CaMKII knockout, the neonatal ventral hippocampus lesion, and the NMDA-antagonism based models of schizophrenia show decreased CaMKII activity associated to a schizophrenia-like profile, thereby suggesting CaMKII as a potential therapeutic target in schizophrenia.